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Background: The tetrazolium-based MTT assay has long been regarded as the gold standard of cytotoxicity assays
as it is highly sensitive and has been miniaturised for use as a high-throughput screening assay. However, various
reports refer to interference by different test compounds, including the glycolysis inhibitor 3-bromopyruvate, with
the conversion of the dye to coloured formazan crystals. This study assessed the linear range and reproducibility of
three commonly used cell enumeration assays; the neutral red uptake (NRU), resazurin reduction (RES) and sulforhodamine
B (SRB) assays, in comparison to the MTT assay. Interference between the MTT assay and three glycolysis inhibitors,
2-deoxyglucose, 3-bromopyruvate and lonidamine, was investigated.
Results: Data indicate that the NRU, RES and SRB assays showed the smallest variability across the linear range,
while the largest variation was observed for the MTT assay. This implies that these assays would more accurately
detect small changes in cell number than the MTT assay. The SRB assay provided the most reproducible results as
indicated by the coefficient of determination after a limited number of experiments. The SRB assay also produced
the lowest variance in the derived 50% inhibitory concentration (IC50), while IC50 concentrations of 3-bromopyruvate
could not be detected using either the MTT or RES assays after 24 hours incubation. Interference in the MTT assay was
observed for all three tested glycolysis inhibitors in a cell-free environment. No interferences were observed for the
NRU, SRB or RES assays.
Conclusions: This study demonstrated that the MTT assay was not the best assay in a number of parameters that must
be considered when a cell enumeration assay is selected: the MTT assay was less accurate in detecting changes in
cell number as indicated by the variation observed in the linear range, had the highest variation when the IC50
concentrations of the glycolysis inhibitors were determined, and interference between the MTT assay and all the
glycolysis inhibitors tested were observed. The SRB assay performed best overall considering all of the parameters,
suggesting that it is the most suitable assay for use in preclinical screening of novel therapeutic compounds with
oxido-reductive potential.
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Developing a new therapeutic agent from conception,
initial testing in the laboratory to availability on the
market is a long and costly process: it is estimated that
approximately U$868 million is spent on the successful
approval of a single drug [1]. Preclinical testing is vitally
important to eliminate unsuitable candidates before the
expense of clinical research is incurred. The use of cell
culture for the initial preclinical screening of potential
therapeutic compounds has become commonplace as
cultured cells can be selected to represent the disease of
interest or its associated biochemical anomalies [2]. It is
of vital importance to obtain accurate, reliable results
from the in vitro cytotoxicity assays employed in the
initial stages of preclinical research as this data may in-
fluence the success of a drug candidate to proceed into
the development process.
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetra-
zolium bromide (MTT) assay has become the gold stand-
ard for determination of cell viability and proliferation
since its development by Mosmann in the 1980′s [3]. This
assay measures cell viability in terms of reductive activity
as enzymatic conversion of the tetrazolium compound to
water insoluble formazan crystals by dehydrogenases oc-
curring in the mitochondria of living cells although redu-
cing agents and enzymes located in other organelles such
as the endoplasmic reticulum are also involved [4,5]. The
increased sensitivity of the assay and its potential as a
miniaturised high-throughput assay made it a break-
through in cell enumeration technology by replacing the
radioactive isotope based 3H-thymidine incorporation
assay. Initially, the method involved no wash steps, but
called for the solubilisation of the formazan crystals in
acid-isopropanol, a time-consuming procedure [3]. How-
ever several modifications, including the addition of DMF
to solubilise the formazan in aqueous medium [6] or
removing excess dye with gentle aspiration and washing
with PBS followed by solubilising the formazan crystals in
DMSO [7] improved the simplicity and sensitivity of this
assay. Several tetrazolium-based assays, such as the XTT
[8], MTS [9] and WST [10] assays, in which water soluble
formazan products are generated, eliminating the need for
washing and solvent solubilisation steps, have been devel-
oped but have not replaced the well-established MTT
assay.
A recent report indicated that certain glycolysis inhibi-
tors, such as 3-bromopyruvate, interferes with the MTS
assay [11]. A more thorough literature review revealed
that several tetrazolium-based assays, such as the MTT
and MTS assays, show interactions with many phy-
tochemicals demonstrating intrinsic reductive potential
including antioxidants [12,13] and polyphenols [14], com-
pounds generating superoxide such as nano titanium di-
oxide [15], and corrosion products of certain metal alloys[16]. Furthermore, the dependence of the MTT assay on
metabolic function can confound results as a direct correl-
ation between the glucose concentration of the cell culture
medium and the reductive rate of MTT has also been ob-
served [17]. Increased reduction of the MTT dye has been
reported in the presence of liver fractions indicating the
reductive potential of various hepatic cytosolic and micro-
somal enzymes [18].
In this study the MTT assay, considered by many to
be the ‘gold standard’, was compared to three commonly
used cell enumeration assays: the neutral red uptake
assay (NRU), resazurin reduction assay (RES) and the
sulforhodamine B assay (SRB). The tetrazolium-based
MTT assay relies mainly on enzymatic conversion of the
dye to formazan crystals which occurs in numerous
organelles including the mitochondria and endoplasmic
reticulum [5,6] however it has become evident that
many endogenous and exogenous compounds can also
catalyse this chemical change. The conversion of resazurin
to fluorescent resorufin occurs mostly in the mitochondria
and the quantity of resorufin generated can therefore be
used as indicator of metabolic activity [19]. The neutral
red uptake assay relies on the intracellular accumulation
of the dye in cellular lysosomes via active transport [20].
The sulforhodamine B assay in contrast measures total
cellular protein content and does not rely on cell function-
ality [21,22]. At present the SRB assay is the preferred
high-throughput assay of the National Cancer Institute
(NCI) in the USA and is the assay used in the NCI’s lead
compound screening programme [21-23].
When considering a cell enumeration assay a number
of variables must be taken into account including poten-
tial interferences, linearity, sensitivity and reproducibility
of the assay. Assays used in the initial screening of poten-
tial anticancer compounds must be sufficiently sensitive to
detect small differences in cell number, yet robust enough
to generate reproducible results under various controlled
experimental conditions. Further advantages for an assay
are a simple experimental procedure so that reliable data
is obtained from the first experiment and the potential
for automation. These characteristics would ensure that
in vitro cytotoxicity data can be obtained in a time- and
cost-effective manner.
Based on these reports the potential for interference
between the MTT assay and two hexokinase inhibitors
as well as lonidamine which all inhibit the glycolysis
pathway were investigated. The hexokinase inhibitors,
2-deoxyglucose (2DG) and 3-bromopyruvate (3-BrPA),
abrogate the conversion of glucose to glucose-6-phosphate
by hexokinases [24]. In contrast, exposure to lonidamine
(LON) results in damage to the mitochondria and ultim-
ately the cessation of glycolysis [25]. Aerobic glycolysis is
the favoured energy production pathway of cancerous
tissue, a phenomenon known as the Warburg effect
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under aerobic conditions as glycolysis leads to the gen-
eration of only two molecules of ATP per molecule of
glucose used, whereas the Krebs cycle produce 36 mole-
cules of ATP for every molecule of glucose consumed
[27]. The conversion of glucose to glucose-6-phosphate
by hexokinases is the only rate-limiting step in the
glycolytic pathway and therefore a very attractive target
for potential chemotherapeutic agents [28]. Furthermore,
as these inhibitors exert an effect on mitochondrial activ-
ity the probability that these glycolysis inhibitors could
interfere with cell enumeration assays should be consid-
ered before experimental protocols are finalised.
To determine the most reliable and sensitive cell enu-
meration assay for preliminary screening of potential
anticancer agents in the presence of co-administered
glycolysis inhibitors prompted an investigation of the
linear range, reproducibility, potential interference and
cost-effectiveness of four commonly used cell enumer-
ation assays used in cytotoxicity evaluation.
Methods
Cell culture
Approval for the use of commercially available cell cul-
ture was obtained from the Research Ethics Committee
of the University of Pretoria (307–2013).
MDA-MB-231, MCF-7 and MCF-12A cell lines were
purchased from the American Type Culture Collection.
Tissue culture medium and supplements, dyes, glycolysis
inhibitors and dimethyl sulfoxide were obtained from
Sigma-Aldrich Chemical Co (St Louis, USA). Phosphate
buffered saline (PBS) was procured from BD Biosciences
(Sparks, USA) and foetal bovine serum (FCS) from PAA
Laboratories (Pasching, Austria).
Linear range
To determine the linear range of each assay, six cell dens-
ities ranging from 50 – 10 000 cells/well were plated into
sterile 96-well plates and incubated for 24- or 72 hours in
the absence of glycolysis inhibitors before performing one
of the four cell enumeration assays.
Reproducibility
To investigate the reproducibility of each assay, cells were
plated into sterile 96-well plates at a concentration of 500
cells/well and allowed to attach for 24 hours before ex-
posure to varying concentrations of 3-bromopyruvate,
lonidamine or 2-deoxyglucose. Internal triplicates for each
concentration were included in each experiment. After a
further 24- or 72 hours incubation period, cell enumer-
ation assays were performed. From the data obtained after
four independent experiments the concentration of each
inhibitor which inhibits 50% cell viability (IC50) as mea-
sured by each enumeration assay with triplicate repeatswas determined using GraphPad Prism® version 4.0 for
Windows (GraphPad Software, San Diego California USA,
www.graphpad.com) and the variability of the IC50 con-
centrations was compared.Interference
To investigate potential interference of each cell enu-
meration assay by the glycolysis inhibitors, the assay
dyes were diluted as required in PBS until an absorbance
reading of approximately 1.2 was obtained in sterile 96-
well microtitre plate wells. The glycolysis inhibitors
were also diluted in PBS and added to the dyes. After
an incubation period of 4 hours, the absorbance was
determined spectrophotometrically at the wavelengths
used for each assay. Three independent experiments
were performed.Cell enumeration assays
Neutral Red Uptake assay (NRU)
The NRU method was used as previously described [29].
After a 24- or 72 hours incubation period, the 96-well
microtitre plate was centrifuged (230 g for 10 minutes)
and the medium was removed using a multichannel auto
pipette. Neutral red stain (100 μl of a 0.2 mg/ml in cell
culture medium) was added to each well and the plate
was re-incubated at 37°C for 4 hours. Thereafter the
plate was washed with PBS that was removed then,
allowed to dry for approximately 1 hour and 100 μl of
neutral red eluent (EtOH:dH2O:acetic acid 50:49:1)
added to each well. The microtitre plate was placed on a
shaker for 1 hour in order to dissolve the dye. After the
neutral red had dissolved, the absorbance of the plate
was determined spectrophotometrically at 540 nm with
a reference wavelength of 630 nm using an ELX800 UV
universal microplate reader (Bio-Tek Instruments Inc.,
Vermont, USA).MTT assay
The MTT staining method as described by Mosmann [3]
was used with minor modifications [7]. After a 24- or
72 hour incubation period, 20 μl of a 5 mg/ml MTT
solution was added to each well and the plate was
further incubated at 37°C for 4 hours. Thereafter the
medium was aspirated and the wells washed with PBS,
allowed to dry for approximately 2 hours and 200 μl of
DMSO was added to each well. The microtitre plate was
placed on a shaker in order to dissolve the dye. After the
formazan crystals had dissolved, the absorbance was
determined spectrophotometrically at 570 nm using a
reference wavelength of 630 nm on an ELX800 UV
universal microplate reader (Bio-Tek Instruments Inc.,
Vermont, USA).
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This assay was performed colorimetrically as previously
described [19]. After a 24- or 72 hours incubation period,
the 96-well microtitre plate was centrifuged (230 g for
10 minutes) and the medium removed using a multichan-
nel auto pipette. Resazurin stain (100 μl of 0.025 mg/ml in
PBS) was added to each well using a multichannel auto
pipette and the plate re-incubated at 37°C for 4 hours.
Thereafter the absorbance was determined spectropho-
tometrically at 570 nm using a reference wavelength of
630 nm on an ELX800 UV universal microplate reader
(Bio-Tek Instruments Inc., Vermont, USA).
Sulforhodamine B assay (SRB)
The assay was done according to the method described by
Vichai and Kirtikara [22]. After a 24- or 72 hours incuba-
tion period, cells were fixed by adding trichloroacetic acid
to a final concentration of 10% trichloroacetic acid to the
wells and the plate was incubated at 4°C for 24 hours.
Thereafter, the plate was gently washed under flowing tap
water and allowed to dry for approximately 1 hour before
staining with 100 μl of SRB stain (0.057% in 1% acetic
acid). After 30 minutes the plate was washed with 1%
acetic acid to remove excess stain. The plate was again
allowed to dry for approximately 30 minutes. A volume of
200 μl of TRIS buffer (10 mM, pH 10.5) was added and
the plate was placed on a shaker to dissolve the stain for
approximately 30 minutes. The absorbance was deter-
mined spectrophotometrically at 540 nm using a reference
wavelength of 630 nm on an ELX800 UV universal micro-
plate reader (Bio-Tek Instruments Inc., Vermont, USA).
Interpretation of results
A minimum of three independent experiments with a
minimum of eight internal replicates were performed to
determine the linearity of each cell enumeration assay. For
reproducibility and interference experiments a minimumTable 1 A summary of the advantages and disadvantages of
Advantages
Neutral red uptake assay 1. Cell enumeration independent of enzymati
conversion of dye [30,31]
2. Few wash steps involved [30,31]
MTT assay 1. Gold standard for cytotoxicity testing
2. Suitable for high-throughput screening and
miniaturisation [34]
Resazurin reduction assay 1. Few wash steps involved [19]
2. Follow-up assays can be performed on sam
cells as assay is not cytotoxic [32,35]
Sulforhodamine B assay 1. Cell enumeration dependent on protein co
thus no test compound interference [21,22
2. Highly reproducibleof three independent experiments with a minimum of
three internal replicates were performed. All data was
blank adjusted prior to further interpretation. All statis-
tical calculations and generation of graphs were com-
pleted using GraphPad Prism® version 4.0 for Windows
(GraphPad Software, San Diego California USA, www.
graphpad.com).Results and discussion
To aid with the discussion, some advantages and disad-
vantages of each cell enumeration assay are listed in
Table 1. Although numerous studies have compared cell
enumeration assays, this appears to be the first report
comparing the NRU, MTT, RES and SRB in vitro assays
under the same conditions. This study compared the cell
enumeration assays based on linear range, reproducibility
and interference with glycolysis inhibitors.Linear range
The linear range of each assay using a range of cell
concentrations over 24- and 72 hours incubation with-
out any drug exposure revealed comparable results for
the three different cell lines used. The results obtained
for the MDA-MB-231 cell line with the 95% confidence
bands indicated, indicating the percentage of the data
which can be explained by regression analysis, as well as
the absorbance obtained for 50 and 100 cells/well are
shown in Figure 1. After both incubation periods, the
SRB assay shows the lowest variability as seen with the
narrow 95% confidence bands, indicating that this assay
is potentially the most accurate and sensitive to changes
in cell number. The largest variation in linear range was
observed for the MTT assay, indicating that operator
experience with the assay as well as numerous other
experimental parameters may influence the results
obtained.the four cell enumeration assays
Disadvantages
c 1. Some reports of test compound interference [32]
1. Conversion to formazan crystals depends on metabolic
rate and number of mitochondria resulting in many known
interferences [4,12-17,33]
2. Numerous wash steps required [3,7]
1. Conversion to resorufin depend on enzymatic conversion [18]




1. Numerous wash steps involved, but fixation required [22]
2. Less sensitive with non-adherent cells
Figure 1 The linear range of the four cell enumeration assays using MDA-MB-231 cells. Four different cell enumeration assays were
performed after 24 and 72 h incubation periods at six increasing starting cell densities. The solid line represents the linear least squares fit of the
data. The dashed lines represent the 95% confidence bands. Graphs for 24 h incubation period depicts cell density up to 10 000 cells/well and
72 h incubation period depicts cell density up to 5 000 cells/well (n = 4).
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the MTT assay at the lowest seeding densities after
24 hours suggest that this assay is less sensitive at cell
numbers below 1000 cells/well. The RES and SRB
assays were able to detect differences in cell number
as low as 500 cells/well accurately. Even though low seed-
ing densities are not often employed, the cytotoxic
effects of novel therapeutic agents may lead to such
diminished cell numbers. For the screening of noveltherapeutic agents the SRB assay seems superior to the
MTTassay due to greater sensitivity.
It is evident that the absorbance signal is directly pro-
portional to the cell number, which is expected to in-
crease with incubation time. This is most clearly seen
after 72 h incubation where the MTT assay was perfor-
med (Figure 1). Some reports have however indicated
that the quantity of formazan crystals produced is not
solely dependent on cell number [33,36]. The MTT assay
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zan by mainly mitochondrial succinic dehydrogenases,
although cytosolic enzymes such as nicotinamide aden-
ine dinucleotide (NADH) reductase and flavin oxidase
may also be involved [4]. The rate of the conversion to
the formazan has been shown to be linked to the meta-
bolic activity of the cell and therefore decreased intracel-
lular glucose concentrations may result in a decrease in
the amount of formazan crystals produced [36]. Another
factor reported to influence the conversion to formazan
is the number of mitochondria present in the cell. Ac-
cordingly, larger cells with more mitochondria have a
higher rate of tetrazolium conversion [33]. Defective
mitochondria have also been reported to retain the ability
to reduce tetrazolium [37]. Taken together these factors
may lead to a false estimation of cell number.
The coefficient of determination (r2), indicative of how
closely the growth curve generated can be fitted with
non-linear regression statistics for the cell lines and in-
cubation periods tested, is shown in Table 2. An r2 value
of less than 0.9 was calculated for the MTT and NRU as-
says after 24 h incubation using the MCF-7 and MCF-
12A cell lines respectively while an r2 value of less than
0.9 was calculated for the MTT and RES assays after
72 h incubation. The SRB assay was the only assay for
which the non-linear regression statistics could be fitted
closely to experimental data obtained after both these
incubation times tested, suggesting that the most reliable
results will be obtained using the SRB assay.
Data obtained during this study regarding the wide
linear range of the SRB assay confirms published results
[38]. The highest average coefficient of determination
was calculated for the SRB assay indicating greater pre-
dictive power of the assay. Of the four assays, the SRB
assay is the only true cell enumeration method as it does
not rely on a metabolic function or activity of live cells
for quantification of cell number [22]. Instead the assay
relies on the ability of SRB to bind to basic amino
acids under slightly acid conditions, while bound stain
is released under strongly basic conditions [22]. ThisTable 2 The coefficient of determination (r2) of the four
cytotoxicity assays
Cell lines and incubation periods NRU MTT RES SRB
MCF-7 24 hours incubation 0.901 0.711 0.999 0.992
MDA-MB-231 0.979 0.975 0.998 0.999
MCF-12A 0.846 0.903 0.976 0.999
MCF-7 72 hours incubation 0.994 0.762 0.915 0.999
MDA-MB-231 0.958 0.878 0.843 0.973
MCF-12A 0.986 0.990 0.887 0.985
Average 0.937 0.864 0.934 0.991
The neutral red, MTT, resazurin reduction and SRB assays were performed after
24 or 72 hour incubation on three cell lines (n = 4).approach eliminates the influence of varying biological
parameters, such as increased metabolic rate or cellular
mitochondria number on the quantification process. This
data indicates that the SRB assay appears to be the
most effective in detecting small or large changes in
cell number.
Hamid and colleagues who conducted an extensive
study comparing the MTT and RES assays, concluded
that while both assays are useful as cytotoxicity assays,
the RES assay is more suited for HTS as it is more sensi-
tive [34]. In the present study the linear range for the
RES assay was slightly wider than that determined for
the MTT assay; but more importantly the overall coeffi-
cient of determination calculated for the RES assay was
better than that of the MTT assay. It should be consid-
ered, however, that an absorbance-based version of the
RES assay was used in this study and that the sensitivity
and selectivity of the assay would be further enhanced
using fluorescence detection. In contrast to the MTT
assay, the resazurin reduction assay offers the advantage
of allowing follow-up assays as the reagents and the dye
used in the RES assay do not influence cell viability [35].
Unlike the MTT and other tetrazolium-based assays
which abrogate respiration, the RES dye acts as an elec-
tron acceptor in the last step in the respiratory chain
and does not produce a toxic effect [32]. Unfortunately,
FCS has been reported to interfere in the RES assay [19],
but this obstacle may be easily overcome by removing
cell culture medium at the end of the incubation period
and using serum free media as a solvent for the resazurin
dye instead of complete cell culture medium.
Reproducibility
Enhanced reproducibility translates into requiring fewer
experimental repeats, and thus less reagent and consum-
ables, to obtain reliable data. The implication regarding
costs and experimental time cannot be underestimated.
Comparing the reproducibility of the assays obtained in
the IC50 concentrations of the glycolysis inhibitors calcu-
lated after four independent experiments with internal
triplicates provides an effective means to rank the assays
according to reproducibility. Results for the non-linear
regression statistics were used to generate the dose–re-
sponse curves for each assay on the MCF-7 cell line after
24- and 72 h incubation periods (Figure 2). It appears
that the data points for the MTT and SRB assays most
closely resemble the dose–response curves suggesting
that these assays would produce the most reliable re-
sults. After three experimental repeats, the SRB assay
showed the lowest overall variability at both the 24- and
72 h time points and for all three cell lines tested
(Table 3) implying that fewer experimental repeats
would be required with this assay to obtain reliable
results.
Figure 2 The effect of 3-bromopyruvate on the growth of MCF-7 cells. The graphs represent results obtained after 24 and 72 hours
incubation as assayed by the four cell enumeration assays. Note that the error bars are smaller in the 72 hour incubation graphs and in many of
the data points fall within the symbol (n = 3).
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could only be determined at both incubation time points
using the NRU and SRB assays, but not with the MTT
assay (Figure 2, Additional file 1) which may indicate a
lack of sensitivity of this assay. However, a previous
study reported an IC50 concentration of 84.6 ± 15.4 μM
for 3-BrPA using MCF-7 cells after 16 h incubation
using the MTT assay where the formazan crystals weresolubilised using an isopropanol solution [39]. After 16 h
incubation, only a small percent of the MCF-7 cells
would have divided and fewer cells would be available to
convert the tetrazolium dye into the formazan product,
suggesting that an IC50 concentration after 24 h should
be possible. However, the difference in the solubilisation
solvent used, isopropanol as opposed to DMSO, could
influence the results obtained.
Figure 3 Interference of three glycolysis inhibitors with the
MTT assay in a cell-free system. After 4 hours incubation with (A)
2-deoxyglucose, (B) 3-bromopyruvate and (C) lonidamine interference
was seen for the MTT assay (n = 3).
Table 3 The IC50 concentrations of 3-bromopyruvate
calculated for MCF-7 cells after 24 or 72 hour incubation
Cytotoxicity assay
NRU MTT RES SRB
24 hour Incubation 54.1 ± 1.6 - - 86.4 ± 1.2
72 hour incubation 60.9 ± 1.3 98.5 ± 1.1 105.9 ± 1.1 74.4 ± 1.1
Where no values are given these could not be calculated as the assay reported
relative cell survival of greater than 50% at the tested concentrations (n = 4).
Results are indicated as mean ± SEM.
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The potential interference between the glycolysis inhibi-
tors and the dyes used in each of the cell enumeration
assays were investigated using cell free assays and the
results shown in Figure 3. The absorbance of the tetra-
zolium dye used in the MTT assay does not remain con-
stant when any of the glycolysis inhibitors are incubated
with the dye for 4 h in a cell free system. Interestingly,
the absorbance does not demonstrate a consistent dose
dependent change in the presence of all of the glycolysis
inhibitors: the absorbance increases in a dose-dependent
manner when exposed to 3-BrPA, but decreased with
2DG and LON. No interference as measured by colour
change was observed for the NRU, SRB or RES assays with
any of the tested glycolysis inhibitors (see Additional
file 2).
Interference between glycolysis inhibitors and cell enu-
meration assays has been reported previously [11]. Of
the three glycolysis inhibitors selected for this study, 3-
bromopyruvate and 2-deoxyglucose inhibit hexokinase,
the enzyme responsible for the conversion of glucose to
glucose-6-phosphate in the first rate-limiting step of the
glycolytic pathway [24]. The glucose analogue 2DG com-
petes for conversion by hexokinase with glucose. The
product of this conversion, 2-deoxyglucose-6-phosphate,
is not metabolised by downstream hydrolytic enzymes
and thus the cells slowly starve [24].
The observed interference between the glycolysis
inhibitors and the tetrazolium MTT dye was significant
(approximately 2-fold increase in absorbance) and strongly
suggests that this assay is not suitable for use with glycoly-
sis inhibitors. This confirms previously published data on
the interaction between 3-BrPA and tetrazolium-based
assays [11]. Data obtained in this study suggests interfer-
ence of the MTT assay by 2DG. However, previous studies
using 2DG and the MTT assay have been reported
without any mention of interference by 2DG [40]. The
decreased absorbance noted after incubation of MTT with
2DG and LON cannot be explained based on the available
information and the mechanism involved should be inves-
tigated further. Interestingly the RES assay, which relies
on a similar reduction mechanism as the MTT assay, did
not show interference from any of the three glycolysis
inhibitors (Additional file 1). The lack of interferenceobserved for the SRB and NRU assays could be explained
by the different dye binding targets providing the colour
in these assays. To the author’s knowledge no reports
on interference with the SRB assay by experimental com-
pounds have been published to date.
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Although generally accepted as the ‘gold standard’, this
study showed that the MTT assay was not the best cell
enumeration assay when considering a number of pa-
rameters that must be weighed up when a cell enumer-
ation assay is selected: the linear range of the MTT assay
showed the highest variability which suggests compro-
mised accuracy; it showed high variation in the cal-
culated IC50 concentrations of the glycolysis inhibitors
after a set number of experiments; interference between
the MTT assay and all of the tested glycolysis inhibitors
were observed. This study has highlighted that there can
be problems with the MTT assay which should be
noted. Cell enumeration assays to be used to assess
new potential drugs or combinations should be assessed
for potential interference by the compounds and suitabil-
ity determined prior starting the evaluation.
Overall, the SRB assay performed best when all test pa-
rameters were considered, suggesting that this assay would
be the most time- and cost-effective assay for preliminary
cytotoxicity screening. It is therefore recommended that
the SRB assay replace the MTT assay as the cell enumer-
ation assay of choice in preclinical testing of potential
therapeutic agents having oxido-reductive potential.
Additional files
Additional file 1: The IC50 concentrations of 3-bromopyruvate
calculated for MCF-7 cells after 24 or 72 hour incubation calculated
per experimental repeat. Results are indicated as IC50 ± SEM. Where no
values are given these could not be calculated as the assay reported relative
cell survival of greater than 50% at the tested concentrations (n = 4).
Additional file 2: Interference of three glycolysis inhibitors with the
NRU, RES and SRB assays in cell-free systems (n = 3).
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